SEC Form 4
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
|
| OMB APPROVAL |
| OMB Number: |
3235-0287 |
| Estimated average burden |
| hours per response: |
0.5 |
|
|
|
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b). |
|
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. |
1. Name and Address of Reporting Person*
| C/O JASPER THERAPEUTICS, INC. |
| 2200 BRIDGE PKWY, SUITE 102 |
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Jasper Therapeutics, Inc.
[ JSPR ]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
Director |
|
10% Owner |
| X |
Officer (give title below) |
|
Other (specify below) |
|
Chief Operating Officer |
|
|
|
3. Date of Earliest Transaction
(Month/Day/Year)
06/12/2024
|
4. If Amendment, Date of Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check Applicable Line)
| X |
Form filed by One Reporting Person |
|
Form filed by More than One Reporting Person |
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
|---|
| 1. Title of Security (Instr.
3)
|
2. Transaction Date
(Month/Day/Year) |
2A. Deemed Execution Date, if any
(Month/Day/Year) |
3. Transaction Code (Instr.
8)
|
4. Securities Acquired (A) or Disposed Of (D) (Instr.
3, 4 and 5)
|
5.
Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr.
4)
|
7. Nature of Indirect Beneficial Ownership (Instr.
4)
|
| Code |
V |
Amount |
(A) or (D) |
Price |
| Voting Common Stock |
06/12/2024 |
|
M
|
|
900 |
A |
$7.1
|
25,909 |
D |
|
| Voting Common Stock |
06/12/2024 |
|
S
|
|
900 |
D |
$24.155
|
25,009 |
D |
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
|
|---|
| 1. Title of Derivative Security (Instr.
3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Transaction Date
(Month/Day/Year) |
3A. Deemed Execution Date, if any
(Month/Day/Year) |
4. Transaction Code (Instr.
8)
|
5.
Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
3, 4 and 5)
|
6. Date Exercisable and Expiration Date
(Month/Day/Year) |
7. Title and Amount of Securities Underlying Derivative Security (Instr.
3 and 4)
|
8. Price of Derivative Security (Instr.
5)
|
9.
Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
4)
|
10. Ownership Form: Direct (D) or Indirect (I) (Instr.
4)
|
11. Nature of Indirect Beneficial Ownership (Instr.
4)
|
| Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
| Stock Option (right to buy) |
$7.1
|
06/12/2024 |
|
M
|
|
900 |
|
|
05/31/2030 |
Voting Common Stock |
900 |
$0.00
|
15,572 |
D |
|
| Explanation of Responses: |
|
|
|
| Remarks: |
|
|
/s/ Jeet Mahal |
06/12/2024 |
|
** Signature of Reporting Person |
Date |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * If the form is filed by more than one reporting person,
see
Instruction
4
(b)(v). |
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure. |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
Exhibit 24
POWER OF ATTORNEY
Know all by these presents, that the undersigned
hereby constitutes and appoints each of Ronald Martell and Herb Cross, signing singly, the undersigned’s true and lawful attorney-in-fact
and agent to:
(1)
execute for and on behalf of the undersigned, an officer, director and/or holder of 10% or more of a registered class of securities of
Jasper Therapeutics, Inc., a Delaware corporation (the “Company”), Forms 3, 4 and 5 in accordance with Section 16(a)
of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder or Forms 144 in accordance with Rule 144 (“Rule
144”) under the Securities Act of 1933, as amended;
(2)
do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such
Form 3, 4, 5 and 144, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the
United States Securities and Exchange Commission and any stock exchange or similar authority, as required; and
(3)
take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of any such attorney-in-fact, may
be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by
such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms
and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.
The undersigned hereby grants to each such attorney-in-fact
full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally
present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s
substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned,
are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended, or Rule 144.
This Power of Attorney shall remain in full force
and effect with respect to the undersigned until the earliest to occur of (a) such date that the undersigned is no longer required to
file Forms 3, 4, 5 and 144 with respect to the undersigned’s holdings of and transactions in securities issued by the Company,
or (b) the revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact. This Power
of Attorney shall terminate with respect to each of the foregoing attorneys-in-fact at such time as such attorney-in-fact is no longer
employed by the Company or any of its subsidiaries.
IN WITNESS WHEREOF, the undersigned has caused
this Power of Attorney to be executed as of this 29th day of May, 2024.
| /s/ Jeet Mahal |
|
| Signature |
|
| |
|
| Name: |
Jeet Mahal |
|
Exhibit 24
POWER OF ATTORNEY
Know all by these presents, that the undersigned
hereby constitutes and appoints each of Ronald Martell and Herb Cross, signing singly, the undersigned’s true and lawful attorney-in-fact
and agent to:
(1)
execute for and on behalf of the undersigned, an officer, director and/or holder of 10% or more of a registered class of securities of
Jasper Therapeutics, Inc., a Delaware corporation (the “Company”), Forms 3, 4 and 5 in accordance with Section 16(a)
of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder or Forms 144 in accordance with Rule 144 (“Rule
144”) under the Securities Act of 1933, as amended;
(2)
do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such
Form 3, 4, 5 and 144, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the
United States Securities and Exchange Commission and any stock exchange or similar authority, as required; and
(3)
take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of any such attorney-in-fact, may
be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by
such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms
and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.
The undersigned hereby grants to each such attorney-in-fact
full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally
present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s
substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned,
are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended, or Rule 144.
This Power of Attorney shall remain in full force
and effect with respect to the undersigned until the earliest to occur of (a) such date that the undersigned is no longer required to
file Forms 3, 4, 5 and 144 with respect to the undersigned’s holdings of and transactions in securities issued by the Company,
or (b) the revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact. This Power
of Attorney shall terminate with respect to each of the foregoing attorneys-in-fact at such time as such attorney-in-fact is no longer
employed by the Company or any of its subsidiaries.
IN WITNESS WHEREOF, the undersigned has caused
this Power of Attorney to be executed as of this 29th day of May, 2024.
| /s/ Jeet Mahal |
|
| Signature |
|
| |
|
| Name: |
Jeet Mahal |
|
Grafico Azioni Jasper Therapeutics (NASDAQ:JSPRW)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Jasper Therapeutics (NASDAQ:JSPRW)
Storico
Da Nov 2023 a Nov 2024
